GRPR (gastrin-releasing peptide receptor)
GRPR is a hormone receptor abundant in early and hormone-sensitive prostate cancer, imaged and treated with bombesin-like radioligands.
GRPR is overexpressed in primary and hormone-naive prostate cancer, often in PSMA-negative tumours, and in breast cancer. 68Ga-RM2 PET and 177Lu-NeoB (Novartis) are in clinical trials; complementary theranostic target to PSMA.
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · GRPR is a hormone receptor abundant in early and hormone-sensitive prostate cancer, imaged and treated with bombesin-like radioligands.
- 1 · What it is
GRPR is a hormone receptor abundant in early and hormone-sensitive prostate cancer, imaged and treated with bombesin-like radioligands.
- 2 · What goes wrong in cancer
G-protein-coupled receptor for bombesin/GRP; expression falls with castration resistance.
- 3 · How drugs use it
No product in this corpus aims at GRPR (gastrin-releasing peptide receptor) yet. Because it sits on the outside of the cell, it can be reached from the bloodstream: antibodies flag the cell, ADCs deliver a toxin, radioligands deliver radiation, and CAR-T or bispecifics bring a T cell.
Biology
G-protein-coupled receptor for bombesin/GRP; expression falls with castration resistance.
- Hormone-sensitive prostate cancer
- ER+ breast cancer
- GIST
Latest papers
topQuery for this target: (TITLE:"GRPR" OR ABSTRACT:"GRPR" OR TITLE:"gastrin-releasing peptide receptor" OR ABSTRACT:"gastrin-releasing peptide receptor") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about GRPR (gastrin-releasing peptide receptor), not a curated reading list.